A transcriptomic study reveals beneficial effects of HsTX1[R14A] on the cognition of a mouse model of sporadic Alzheimer’s disease

Neuroinflammation is a key pathological feature of Alzheimer’s disease (AD), which can be partly attributed to the chronic activation of microglia. The voltage‐gated potassium channel 1.3 (Kv1.3) is selectively upregulated in pro‐inflammatory microglia, making it an ideal therapeutic target to modulate microglia‐mediated neuroinflammation. A highly potent and selective Kv1.3 blocker (HsTX1[R14A]) developed in our laboratory can effectively suppress neuroinflammation. More importantly, chronic subcutaneous dosing of HsTX1[R14A] (1 mg/kg every 2 day) over 8 weeks improved cognitive function in a mouse model of sporadic AD, senescence accelerated mouse‐prone 8 (SAMP8). The current transcriptomic study is to explore the therapeutic benefits in the SAMP8 mouse brains from chronic dosing of HsTX1[R14A].